{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T21:28:51Z","timestamp":1764192531540},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Robert Koch-Institut"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Die Weltgesundheitsorganisation (WHO) hat 2016 eine Strategie zur Eliminierung von Hepatitis-B-, -C- und -D-Virusinfektionen verfasst und Indikatoren zum Monitoring des Fortschritts definiert. Das Robert Koch-Institut hat 2019 ein interdisziplin\u00e4res Arbeitstreffen zur Verbesserung der Datenlage veranstaltet.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ziele<\/jats:title>\n                <jats:p>Ziele waren die Vernetzung der Akteure, die Erstellung einer \u00dcbersicht zu den in Deutschland vorhandenen Datenquellen zu Hepatitis\u00a0B, C und\u00a0D und die Diskussion methodischer Aspekte.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material und Methoden<\/jats:title>\n                <jats:p>Die f\u00fcr Deutschland relevanten WHO-Indikatoren wurden extrahiert und es wurde bestimmt, wie diese anhand vorliegender Daten konstruiert werden k\u00f6nnen. Bei dem Arbeitstreffen mit AkteurInnen aus dem \u00f6ffentlichen Gesundheitsdienst, aus Kliniken, Laboren, von Krankenkassen, Forschungsinstituten, Datenhaltern und Registern wurden in Arbeitsgruppen Erhebungsmethoden diskutiert, welche dazu dienen k\u00f6nnen, fehlende Daten zu ermitteln. Die Datenquellen und Daten wurden hinsichtlich Qualit\u00e4t, Vollst\u00e4ndigkeit sowie praktischer Umsetzbarkeit evaluiert und priorisiert.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>F\u00fcr die Allgemeinbev\u00f6lkerung k\u00f6nnen die Indikatoren zu Pr\u00e4vention, Testung, Diagnose, Behandlung, Heilung, Folgesch\u00e4den und Mortalit\u00e4t aus Diagnose\u2011, Versorgungs- und Registerdaten, Daten aus Laboren und klinischen Zentren sowie einzelnen Studien konstruiert werden. Datenquellen f\u00fcr vulnerable Gruppen beschr\u00e4nken sich auf einzelne Studien zu Drogengebrauchenden, M\u00e4nnern, die Sex mit M\u00e4nnern haben, und HIV-Ko-Infizierten. Daten f\u00fcr MigrantInnen, Inhaftierte und SexarbeiterInnen sind kaum verf\u00fcgbar; ebenso fehlen aktuelle Daten zur Krankheitslast chronischer Hepatitisinfektionen in der Allgemeinbev\u00f6lkerung.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Diskussion<\/jats:title>\n                <jats:p>F\u00fcr alle ausgew\u00e4hlten Indikatoren konnten Datenquellen, ihre Besonderheiten und Limitationen identifiziert werden. Im n\u00e4chsten Schritt gilt es, die entwickelten Ideen in konkrete Projekte mit einzelnen Datenhaltern umzusetzen.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00103-020-03260-2","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T04:03:27Z","timestamp":1608091407000},"page":"77-90","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Wie l\u00e4sst sich die Eliminierung von Hepatitis\u00a0B, C und\u00a0D in Deutschland messen? Ergebnisse eines interdisziplin\u00e4ren Arbeitstreffens","How to assess the elimination of viral hepatitis\u00a0B, C, and\u00a0D in Germany? Outcomes of an interdisciplinary workshop"],"prefix":"10.1007","volume":"64","author":[{"name":"die Hepatitis-Monitoring-Arbeitsgruppe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Zimmermann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiebe","family":"K\u00fclper-Schiek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gyde","family":"Steffen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofie","family":"Gillesberg Lassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviane","family":"Bremer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Dudareva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"key":"3260_CR1","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2010","unstructured":"Lozano\u00a0R, Naghavi\u00a0M, Foreman\u00a0K et\u00a0al (2010) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a\u00a0systematic analysis for the Global Burden of Disease Study. Lancet 380:2095\u20132128","journal-title":"Lancet"},{"key":"3260_CR2","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3851\/IMP2654","volume":"18","author":"BC Cowie","year":"2013","unstructured":"Cowie\u00a0BC, Carville\u00a0KS, Maclachlan\u00a0JH (2013) Mortality due to viral hepatitis in the Global Burden of Disease Study 2010: new evidence of an urgent global public health priority demanding action. Antivir Ther 18:953\u2013954","journal-title":"Antivir Ther"},{"key":"3260_CR3","unstructured":"World Health Organization (WHO) (2017) Global hepatitis report 2017. http:\/\/apps.who.int\/iris\/bitstream\/10665\/255016\/1\/9789241565455-eng.pdf?ua=1. Zugegriffen: 31. Mai 2020"},{"key":"3260_CR4","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","volume":"388","author":"JD Stanaway","year":"2016","unstructured":"Stanaway\u00a0JD, Flaxman\u00a0AD, Naghavi\u00a0M et\u00a0al (2016) The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 388:1081\u20131088","journal-title":"Lancet"},{"key":"3260_CR5","unstructured":"World Health Organization (WHO) (2019) Hepatitis D. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-d. Zugegriffen: 13. Okt. 2020"},{"key":"3260_CR6","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","volume":"61","author":"E Gower","year":"2014","unstructured":"Gower\u00a0E, Estes\u00a0C, Blach\u00a0S, Razavi-Shearer\u00a0K, Razavi\u00a0H (2014) Global epidemiology and genotype distribution of the hepatitis C virus infection. J\u00a0Hepatol 61:S45\u2013S57","journal-title":"J Hepatol"},{"key":"3260_CR7","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"A Schweitzer","year":"2015","unstructured":"Schweitzer\u00a0A, Horn\u00a0J, Mikolajczyk\u00a0RT, Krause\u00a0G, Ott\u00a0JJ (2015) Estimations of worldwide prevalence of chronic hepatitis B virus infection: a\u00a0systematic review of data published between 1965 and 2013. Lancet 386:1546\u20131555","journal-title":"Lancet"},{"issue":"10","key":"3260_CR8","doi-asserted-by":"publisher","first-page":"e25691","DOI":"10.1371\/journal.pone.0025691","volume":"6","author":"Y Balabanova","year":"2011","unstructured":"Balabanova\u00a0Y, Gilsdorf\u00a0A, Buda\u00a0S et\u00a0al (2011) Communicable diseases prioritized for surveillance and epidemiological research: results of a\u00a0standardized prioritization procedure in Germany, 2011. Plos One 6(10):e25691. https:\/\/doi.org\/10.1371\/journal.pone.0025691","journal-title":"Plos One"},{"key":"3260_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.00424","author":"I Sperle","year":"2020","unstructured":"Sperle\u00a0I, Steffen\u00a0G, Leendertz\u00a0SA et\u00a0al (2020) Prevalence of Hepatitis B, C, and D in Germany: results from a\u00a0scoping review. Front Public Health. https:\/\/doi.org\/10.3389\/fpubh.2020.00424","journal-title":"Front Public Health"},{"key":"3260_CR10","unstructured":"World Health Organization (WHO) (2016) Global health sector strategy on viral hepatitis 2016\u20132021. Towards ending viral hepatitis. http:\/\/apps.who.int\/iris\/bitstream\/10665\/246177\/1\/WHO-HIV-2016.06-eng.pdf?ua=1. Zugegriffen: 9. Juni 2017 (p\u00a056)"},{"key":"3260_CR11","unstructured":"United Nations (2015) Transforming our world: the 2030 Agenda for Sustainable Development General Assembly resolution A\/RES\/70\/1. http:\/\/www.un.org\/ga\/search\/view_doc.asp?symbol=A\/RES\/70\/1&Lang=E, p\u00a01\u201335. https:\/\/www.un.org\/ga\/search\/view_doc.asp?symbol=A\/RES\/70\/1&Lang=E. Zugegriffen: 15. Juni 2018"},{"key":"3260_CR12","unstructured":"WHO Regional Office for Europe (2017) Action plan for the health sector response to viral hepatitis in the WHO European Region. https:\/\/www.euro.who.int\/__data\/assets\/pdf_file\/0008\/357236\/Hepatitis-9789289052870-eng.pdf?ua=1. Zugegriffen: 25. Aug. 2018"},{"key":"3260_CR13","unstructured":"Bundesministerium F\u00fcr Gesundheit, Bundesministerium F\u00fcr Wirtschaftliche Zusammenarbeit Und Entwicklung (2016) Strategie zur Eind\u00e4mmung von HIV, Hepatitis B und C und anderen sexuell \u00fcbertragbaren Infektionen. Bis 2030 \u2013 Bedarfsorientiert \u00b7 Integriert \u00b7 Sektor\u00fcbergreifend. http:\/\/www.bundesgesundheitsministerium.de\/fileadmin\/Dateien\/5_Publikationen\/Praevention\/Broschueren\/Strategie_BIS_2030_HIV_HEP_STI.pdf. Zugegriffen: 4. Sept. 2018"},{"key":"3260_CR14","unstructured":"World Health Organization (WHO) (2016) Monitoring and evaluation for viral hepatitis B and C: recommended indicators and framework;Technical Report. http:\/\/apps.who.int\/iris\/bitstream\/10665\/204790\/1\/9789241510288_eng.pdf. Zugegriffen: 4. Juni 2018"},{"issue":"Suppl 2","key":"3260_CR15","doi-asserted-by":"publisher","first-page":"e25050","DOI":"10.1002\/jia2.25050","volume":"21","author":"YJ Hutin","year":"2018","unstructured":"Hutin\u00a0YJ, Bulterys\u00a0M, Hirnschall\u00a0GO (2018) How far are we from viral hepatitis elimination service coverage targets? J\u00a0Int AIDS Soc 21(Suppl 2):e25050","journal-title":"J Int AIDS Soc"},{"key":"3260_CR16","unstructured":"European Centre for Disease Prevention and Control (ECDC) (2019) Monitoring the responses to hepatitis B and C epidemics in the EU\/EEA Member States; Technical Report. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/monitoring-responses-hepatitis-b-and-c-epidemics-eueea-member-states-2019. Zugegriffen: 5. Juni 2018"},{"key":"3260_CR17","doi-asserted-by":"publisher","first-page":"e0229166","DOI":"10.1371\/journal.pone.0229166","volume":"15","author":"G Steffen","year":"2020","unstructured":"Steffen\u00a0G, Sperle\u00a0I, Leendertz\u00a0SA et\u00a0al (2020) The epidemiology of Hepatitis B, C and D in Germany: a scoping review. Plos One 15:e229166","journal-title":"Plos One"},{"key":"3260_CR18","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s00103-020-03114-x","volume":"63","author":"MJ Hassenstein","year":"2020","unstructured":"Hassenstein\u00a0MJ, Aarabi\u00a0G, Ahnert\u00a0P et al (2020) Self-reported infections in the German National Cohort (GNC) in the context of the current research landscape. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 63:404\u2013414","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"3260_CR19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00103-013-1673-x","volume":"56","author":"C Poethko-Muller","year":"2013","unstructured":"Poethko-Muller\u00a0C, Zimmermann\u00a0R, Hamouda\u00a0O et al (2013) Die Seroepidemiologie der Hepatitis A, B und C in Deutschland: Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 56:707\u2013715","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"3260_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/INF.0b013e3181ef22d5","volume":"30","author":"W Cai","year":"2011","unstructured":"Cai\u00a0W, Poethko-Muller\u00a0C, Hamouda\u00a0O, Radun\u00a0D (2011) Hepatitis B virus infections among children and adolescents in Germany: migration background as a\u00a0risk factor in a\u00a0low seroprevalence population. Pediatr Infect Dis\u00a0J 30:19\u201324","journal-title":"Pediatr Infect Dis J"},{"key":"3260_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.00424","author":"I Sperle","year":"2020","unstructured":"Sperle\u00a0I, Steffen\u00a0G, Leendertz\u00a0SA et\u00a0al (2020) Prevalence of hepatitis B, C and D in Germany: results from a\u00a0scoping review. Front Public Health. https:\/\/doi.org\/10.3389\/fpubh.2020.00424","journal-title":"Front Public Health"},{"key":"3260_CR22","first-page":"147","volume":"18","author":"Robert Koch-Institut (RKI)","year":"2019","unstructured":"Robert Koch-Institut (RKI) (2019) Impfquoten bei der Schuleingangsuntersuchung in Deutschland 2017. Epidemiol Bull 18:147\u2013153","journal-title":"Epidemiol. Bull."},{"key":"3260_CR23","doi-asserted-by":"publisher","first-page":"476","DOI":"10.4161\/hv.26986","volume":"10","author":"T Rieck","year":"2014","unstructured":"Rieck\u00a0T, Feig\u00a0M, Eckmanns\u00a0T, Benzler\u00a0J, Siedler\u00a0A, Wichmann\u00a0O (2014) Vaccination coverage among children in Germany estimated by analysis of health insurance claims data. Hum Vaccin Immunother 10:476\u2013484","journal-title":"Hum Vaccin Immunother"},{"key":"3260_CR24","series-title":"Saison","doi-asserted-by":"publisher","first-page":"313","DOI":"10.17886\/EpiBull-2018-040","volume-title":"OKaPII-Studie zur Influenza-Impfung: Impfquoten und Impfmotivation bei Klinikpersonal in der Influenza","author":"J Neufeind","year":"2018","unstructured":"Neufeind\u00a0J, Wenchel\u00a0R, B\u00f6deker\u00a0B, Wichmann\u00a0O (2018) OKaPII-Studie zur Influenza-Impfung: Impfquoten und Impfmotivation bei Klinikpersonal in der Influenza-Saison 2016\/2017. Epid Bull 32:313\u2013332. https:\/\/doi.org\/10.17886\/EpiBull-2018-040"},{"key":"3260_CR25","doi-asserted-by":"publisher","first-page":"467","DOI":"10.25646\/6341","volume":"44","author":"B B\u00f6deker","year":"2019","unstructured":"B\u00f6deker\u00a0B, Neufeind\u00a0J, Wichmann\u00a0O (2019) OKaPII: Influenza-Impfquoten- Monitoring im Krankenhaus. Epid Bull 44:467\u2013469. https:\/\/doi.org\/10.25646\/6341","journal-title":"Epid Bull"},{"key":"3260_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-020-03199-4","author":"S Beermann","year":"2020","unstructured":"Beermann\u00a0S, Jacob\u00a0J, Dudareva\u00a0S et\u00a0al (2020) Gelingt das Screening von Schwangeren auf HIV, Syphilis und Hepatitis\u00a0B in Deutschland? Eine Analyse auf Basis von Routinedaten. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. https:\/\/doi.org\/10.1007\/s00103-020-03199-4","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"3260_CR27","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1007\/s00103-010-1152-6","volume":"53","author":"R Offergeld","year":"2010","unstructured":"Offergeld\u00a0R, Ritter\u00a0S, Quabeck\u00a0L, Hamouda\u00a0O (2010) Infektionsepidemiologische Daten von Blutspendern in Deutschland 2007. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 53:1188\u20131196","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"3260_CR28","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00103-012-1516-1","volume":"55","author":"R Offergeld","year":"2012","unstructured":"Offergeld\u00a0R, Ritter\u00a0S, Hamouda\u00a0O (2012) HIV-, HCV-, HBV- und Syphilissurveillance unter Blutspendern in Deutschland 2008\u20132010. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 55:907\u2013913","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"3260_CR29","first-page":"275","volume":"30","author":"L Meurs","year":"2019","unstructured":"Meurs\u00a0L, Dudareva\u00a0S, Diercke\u00a0M, Altmann\u00a0D, Bremer\u00a0V, Zimmermann\u00a0R (2019) Hepatitis-C-Meldedaten nach IfSG, 2016\u20132018: Auswirkungen der \u00c4nderungen von Falldefinition und Meldepflicht. Epidemiol Bull 30:275\u2013228","journal-title":"Epidemiol Bull"},{"key":"3260_CR30","unstructured":"Robert Koch-Institut (RKI) (2018) Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2017. https:\/\/www.rki.de\/DE\/Content\/Infekt\/Jahrbuch\/Jahrbuecher\/2017.html?nn=2374622. Zugegriffen: 27. M\u00e4rz 2019"},{"key":"3260_CR31","unstructured":"Robert Koch-Institut (RKI) (2019) Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2018. https:\/\/www.rki.de\/DE\/Content\/Infekt\/Jahrbuch\/Jahrbuecher\/2018.html?nn=2374622. Zugegriffen: 25. Mai 2020"},{"key":"3260_CR32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.17886\/EpiBull-2018-035","volume":"29","author":"R Zimmermann","year":"2018","unstructured":"Zimmermann\u00a0R, Meurs\u00a0L, Schmidt\u00a0D, Kollan\u00a0C, Dudareva\u00a0S, Bremer\u00a0V (2018) Zur Situation bei wichtigen Infektionskrankheiten in Deutschland. Hepatitis C im Jahr 2017. Epid Bull 29:271\u2013281. https:\/\/doi.org\/10.17886\/EpiBull-2018-035","journal-title":"Epid Bull"},{"key":"3260_CR33","volume-title":"European Scientific Conference on Applied Infectious Disease Epidemiology. ESCAIDE abstract book","author":"K Kremer","year":"2019","unstructured":"Kremer\u00a0K, Dudareva\u00a0S, Zimmermann\u00a0R, An Der Heiden\u00a0M (2019) Number of people living with hepatitis B and C in Germany. In: European Scientific Conference on Applied Infectious Disease Epidemiology. ESCAIDE abstract book Stockholm"},{"key":"3260_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jhep.2017.01.024","volume":"67","author":"R Zimmermann","year":"2017","unstructured":"Zimmermann\u00a0R, Kollan\u00a0C, Ingiliz\u00a0P, Mauss\u00a0S, Schmidt\u00a0D, Bremer\u00a0V (2017) Real-world treatment for chronic hepatitis C infection in Germany: analyses from drug prescription data, 2010\u20132015. J\u00a0Hepatol 67:15\u201322","journal-title":"J Hepatol"},{"key":"3260_CR35","unstructured":"Schmidt D, Kollan C, Ingiliz P, Mauss S, Bremer V, Zimmermann R (2019) Numbers of persons treated with direct-acting antivirals (DAA) for HCV infection in Germany continue to decline (Poster). In: Deutsch-\u00d6sterreichischer AIDS Kongress, D\u00d6AK, Hamburg, 13.\u201315.06.2019"},{"key":"3260_CR36","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1055\/s-0031-1273462","volume":"49","author":"M Cornberg","year":"2011","unstructured":"Cornberg\u00a0M, Protzer\u00a0U, Petersen\u00a0J et al (2011) Aktualisierung der S 3\u2011Leitlinie zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion. Z\u00a0Gastroenterol 49:871\u2013930","journal-title":"Z Gastroenterol"},{"key":"3260_CR37","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/hep.24105","volume":"53","author":"ZH Lin","year":"2011","unstructured":"Lin\u00a0ZH, Xin\u00a0YN, Dong\u00a0QJ et al (2011) Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C\u2011related fibrosis: an updated meta-analysis. Hepatology 53:726\u2013736","journal-title":"Hepatology"},{"key":"3260_CR38","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ijid.2017.10.008","volume":"66","author":"JM Haussig","year":"2018","unstructured":"Haussig\u00a0JM, Nielsen\u00a0S, Gassowski\u00a0M et al (2018) A large proportion of people who inject drugs are susceptible to hepatitis B: results from a\u00a0bio-behavioural study in eight German cities. Int J Infect Dis 66:5\u201313","journal-title":"Int J Infect Dis"},{"key":"3260_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-016-3545-4","volume":"16","author":"B Wenz","year":"2016","unstructured":"Wenz\u00a0B, Nielsen\u00a0S, Gassowski\u00a0M et al (2016) High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a\u00a0cross-sectional study using respondent-driven sampling in eight German cities (2011\u201314). BMC Public Health 16:1\u201314","journal-title":"BMC Public Health"},{"key":"3260_CR40","unstructured":"Robert Koch-Institut (RKI) (2016) Abschlussbericht der Studie \u201eDrogen und chronischen Infektionskrankheiten in Deutschland\u201c (DRUCK-Studie). http:\/\/www.rki.de\/DE\/Content\/InfAZ\/H\/HIVAIDS\/Studien\/DRUCK-Studie\/Abschlussbericht.pdf. Zugegriffen: 5. Juni 2018"},{"key":"3260_CR41","unstructured":"European Centre for Disease Prevention and Control (ECDC) (2013) The EMIS Network. EMIS 2010: The European men-who-have-sex-with-men Internet survey\u2014findings from 38 countries. http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/EMIS-2010-european-men-who-have-sex-with-men-survey.pdf. Zugegriffen: 5. Juni 2018"},{"key":"3260_CR42","unstructured":"European Centre for Disease Prevention and Control (ECDC) (2019) EMIS-2017. The European men-who-have-sex-with-men Internet survey\u2014key findings from 50 countries. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/European-MSM-internet-survey-2017-findings.pdf. Zugegriffen: 30. Juli 2020"},{"key":"3260_CR43","doi-asserted-by":"publisher","first-page":"e0142515","DOI":"10.1371\/journal.pone.0142515","volume":"10","author":"K Jansen","year":"2015","unstructured":"Jansen\u00a0K, Thamm\u00a0M, Bock\u00a0CT et al (2015) High prevalence and high incidence of coinfection with hepatitis B, hepatitis C, and syphilis and low rate of effective vaccination against hepatitis B in HIV-positive men who have sex with men with known date of HIV seroconversion in Germany. Plos One 10:e142515","journal-title":"Plos One"},{"key":"3260_CR44","unstructured":"Schmidt D, Kollan C, Hau\u00dfig J et al (2017) Anhaltende Hepatitis-Ko-Infektionen und HBV-Impfbedarf bei HIV-infizierten Personen in Deutschland \u2013 Daten aus dem Hepatitis Screening in der HIV\u20111 Serokonverterstudie 2012\u20132016. In: D\u00d6AK 2017, Salzburg"},{"key":"3260_CR45","first-page":"382","volume-title":"Gemeinsames Teststellenprojekt 2017","author":"S Schink","year":"2019","unstructured":"Schink\u00a0S, Schafberger\u00a0A, Tappe\u00a0M, Marcus\u00a0U (2019) Gemeinsames Teststellenprojekt 2017. Robert Koch-Institut, Berlin, S 382"},{"key":"3260_CR46","unstructured":"Bundesopiumstelle Des Bundesinstituts Fuer Arzneimittel Und Medizinprodukte (BfArm) (2020) Bericht zum Substitutionsregister 2020. In:Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM), Bonn, p\u00a01\u201310. https:\/\/www.bfarm.de\/SharedDocs\/Downloads\/DE\/Bundesopiumstelle\/SubstitReg\/Subst_Bericht2020.pdf?__blob=publicationFile&v=2. Zugegriffen: 27. Apr. 2020"},{"key":"3260_CR47","first-page":"137","volume":"116","author":"L Kraus","year":"2019","unstructured":"Kraus\u00a0L, Seitz\u00a0NN, Schulte\u00a0B et\u00a0al (2019) Estimation of the number of people with opioid addiction in Germany. Dtsch Arztebl Int 116:137\u2013143","journal-title":"Dtsch Arztebl Int"},{"key":"3260_CR48","series-title":"Infect","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268820000163","volume-title":"Are men who have sex with men in Europe protected from hepatitis\u00a0B? Epidemiol","author":"M Brandl","year":"2020","unstructured":"Brandl\u00a0M, Schmidt\u00a0A, Marcus\u00a0U, An Der Heiden\u00a0M, Dudareva\u00a0S (2020) Are men who have sex with men in Europe protected from hepatitis\u00a0B? Epidemiol Infect 148:e27-e. https:\/\/doi.org\/10.1017\/S0950268820000163"},{"key":"3260_CR49","first-page":"227","volume":"2018","author":"Robert Koch-Institut (RKI)","year":"2018","unstructured":"Robert Koch-Institut (RKI) (2018) Deutsches Elektronisches Melde- und Informationssystem f\u00fcr den Infektionsschutz (DEMIS) \u2013 Entwicklungsschritte. Epidemiol Bull 2018:227\u2013228","journal-title":"Epidemiol. Bull."}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-020-03260-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00103-020-03260-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-020-03260-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T11:04:00Z","timestamp":1609239840000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00103-020-03260-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,16]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["3260"],"URL":"https:\/\/doi.org\/10.1007\/s00103-020-03260-2","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"type":"print","value":"1436-9990"},{"type":"electronic","value":"1437-1588"}],"subject":[],"published":{"date-parts":[[2020,12,16]]},"assertion":[{"value":"24 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"R.\u00a0Zimmermann, W.\u00a0K\u00fclper-Schiek, G.\u00a0Steffen, S.\u00a0Gillesberg Lassen, V.\u00a0Bremer und S.\u00a0Dudareva geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den AutorInnen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}